Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation–Sponsored Workshop. (July 2017)

• Record Type: Journal Article
• Authors: Hesterlee, Sharon; Amur, Shashi; Bain, Lisa J.; Carulli, John; Clarke, Sarah; Day, John W.; Gagnon, Cynthia; Hagerman, Katharine; Heatwole, Chad; Johnson, Nicholas E.; Moxley, Richard; Patel, Nikunj; Thornton, Charles; Kessel, Woodie; White, Molly
• Is Part Of: Therapeutic innovation & regulatory science. Volume 51:Number 4(2017:Jul.)
• Page Start: 516
• Page End: 522
• Publication Date: 2017-07
• Subjects: myotonic dystrophy -- PFDD -- MDHI -- biomarker -- endpoint; Drugs -- Periodicals; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; Drugs -- Testing -- Periodicals; 615.1
• DOI: 10.1177/2168479016683988
• Languages: English
• ISSNs: 2168-4790

Abstract

Myotonic dystrophy (DM) is an autosomal dominant, repeat expansion, progressive disorder with no drug therapies. Consequently, to better define a regulatory pathway in anticipation of new treatment strategies under investigation, the Myotonic Dystrophy Foundation convened a workshop entitled "Patient-Centered Therapy Development for Myotonic Dystrophy" in September 2015. Participants included representatives from academia, industry, the patient community, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). Presenters described the symptom burden of the disease, and existing data on DM biomarkers, endpoints, natural history, and benefit-risk considerations. FDA participants helped clarify the regulatory requirements for new drug treatment approvals and DM-specific issues such as variability, slow progression, and low prevalence. Workshop attendees gained a better understanding of DM and the current status of existing data and tools to support therapeutic drug research and development.